Abstract
ALK, NUT, and TRK are rare molecular aberrations that are pathognomonic for specific rare tumors. In low frequencies, however, they are found in a wide range of other tumor entities. This study aimed to investigate the frequency, association with clinicopathological characteristics, and prognosis of the immunohistochemical expressions of ALK, NUT, and TRK in 477 adenocarcinomas of the stomach and gastroesophageal junction. Seven cases (1.5%) showed an expression of TRK. In NGS, no NTRK fusion was confirmed. No case with ALK or NUT expression was detected. ALK, NUT, and NTRK expression does not seem to play an important role in gastric carcinomas.
Highlights
Gastric cancer is ranked as the sixth most common cancer entity worldwide, having accounted for approximately 780,000 cancer-associated deaths in 2018 [1]
We evaluated the frequency of alterations in Anaplastic lymphoma kinase (ALK), Nuclear protein in testis (NUT), and tropomyosin receptor kinases receptor family (TRKs) in 477 carcinomas of the stomach and gastroesophageal junction
Seven cases (1.5%) with TRK expression were identified by immunohistochemistry (Figure 1A)
Summary
Gastric cancer is ranked as the sixth most common cancer entity worldwide, having accounted for approximately 780,000 cancer-associated deaths in 2018 [1]. Only a few prognostic and therapeutic biomarkers have been identified for gastric cancer. The most important therapeutic marker in gastric carcinoma is HER2 overexpression [2]. MSI status and high PDL1 expression are independent positive prognostic factors in gastric carcinoma [3,4,5], while aberrant E-cadherin expression is considered an unfavorable prognostic factor and even a negative predictive factor for chemotherapy response [6]. MET amplification and overexpression are thought to play a crucial role in gastric carcinogenesis, but this remains to be found as a predictive factor for the response to anti-MET antibodies [5]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
